UroGen Pharma Ltd.

10.85
0.03 (0.28%)
At close: Mar 13, 2025, 11:24 AM
0.28%
Bid 10.68
Market Cap 457.86M
Revenue (ttm) 101.01M
Net Income (ttm) -141.76M
EPS (ttm) -2.96
PE Ratio (ttm) -3.67
Forward PE -3.98
Analyst Buy
Ask 10.78
Volume 38,705
Avg. Volume (20D) 397,351
Open 11.00
Previous Close 10.82
Day's Range 10.72 - 11.14
52-Week Range 9.03 - 20.70
Beta 1.13

About URGN

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms...

Industry Biotechnology
Sector Healthcare
IPO Date May 4, 2017
Employees 235
Stock Exchange NASDAQ
Ticker Symbol URGN
Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for URGN stock is "Buy." The 12-month stock price forecast is $35.5, which is an increase of 227.19% from the latest price.

Stock Forecasts

Earnings Surprise

UroGen Pharma Ltd. has released their quartely earnings on Mar 10, 2025:
  • Revenue of $24.57M misses estimates by $685K, with 4.40% YoY growth.
  • EPS of -0.8 misses estimates by -0.08, with -11.11% YoY decline.
  • Next Earnings Release

    UroGen Pharma Ltd. is scheduled to release its earnings on May 12, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    1 month ago
    +4.63%
    UroGen Pharma shares are trading higher after the ... Unlock content with Pro Subscription
    4 months ago
    +0%
    UroGen Pharma shares are trading higher after the company announced FDA acceptance of its new drug application for UGN-102.